AI-Driven Workflow for Creating Synthetic Patients with Complex Comorbidities

Manual procurement of real-world data for studying disease interactions can stall projects for over a year due to IRB approvals, data use agreements, and de-identification. An automated synthetic generation pipeline delivers statistically valid, privacy-safe cohorts in days, enabling immediate hypothesis testing and model training. This compression of the data acquisition phase is the primary driver of faster time-to-insight for epidemiological studies and therapeutic development.

The workflow embeds differential privacy, automated re-identification risk testing, and governance logging directly into the generation pipeline. This eliminates the need for bespoke legal reviews and lengthy data sharing agreements for each research project. Synthetic data, by design, contains no protected health information (PHI), transforming a high-risk compliance activity into a low-touch, auditable process that satisfies HIPAA and GDPR requirements by default.

Real-world data with specific, multi-morbid patient profiles is often statistically nonexistent, making research into polypharmacy and care pathways impossible. The automated workflow uses graph-based models to enforce physiological plausibility across conditions, generating cohorts with precise, interacting comorbidities on demand. This creates a net-new capability for health economics and outcomes research (HEOR) and care protocol design that was previously cost-prohibitive or unfeasible.

Acquiring and labeling sufficient real patient data for robust AI/ML model training is a major capital expense. This workflow provides an unlimited, on-demand source of high-fidelity training and validation data. By integrating directly with MLops platforms, it allows data scientists to iterate rapidly without budget or privacy constraints, significantly reducing the marginal cost of each experiment and improving model generalizability through greater data diversity.

For MedTech and SaMD developers, demonstrating algorithm efficacy to regulators requires vast, annotated datasets. Generating synthetic DICOM scans and patient records with known, controlled pathologies provides a transparent, auditable evidence base without exposing PHI. This automation creates submission-ready data packages, reducing the risk of delays or rejections due to insufficient or non-compliant real-world data.

The workflow produces a governed, central repository of synthetic patient cohorts that serve as a single source of truth for R&D, commercial, and market access teams. This breaks down data silos, enabling aligned scenario planning for trial design, forecasting, and payer negotiations. The operational leverage comes from transforming data from a project-specific bottleneck into a shared, strategic asset that accelerates decision-making across the organization.

This foundational agent ingests real-world evidence, clinical guidelines, and disease ontologies to construct a probabilistic graph of disease relationships and progression pathways. It models the conditional likelihoods of comorbidities (e.g., how hypertension influences the risk of developing chronic kidney disease) and enforces physiological plausibility rules. This graph serves as the master 'blueprint' for all synthetic patient generation, ensuring cohorts reflect real-world clinical complexity.

A specialized generative agent that uses the comorbidity graph to create individual synthetic patient profiles. It doesn't generate attributes independently; it samples from joint distributions to produce a coherent set of demographics, vital signs, lab values, and medication lists that are consistent with the patient's assigned disease bundle. This agent integrates with models like GANs or diffusion models for structured tabular data, conditioned on the target comorbidity profile.

This LLM-powered agent generates longitudinal clinical narratives (progress notes, discharge summaries) and timestamped event sequences (diagnoses, hospitalizations, medication changes) for each synthetic patient. It ensures narrative coherence with the patient's condition list and simulates a plausible care journey over time. The agent is constrained by clinical knowledge graphs to maintain medical accuracy and formatted for integration with EHR or research database schemas like OMOP CDM.

A critical quality gate, this component uses a team of specialized validator agents to score each synthetic cohort. Agents perform statistical tests (KS, propensity scores), run clinical logic checks (e.g., flagging impossible lab-diagnosis combinations), and simulate privacy attacks to assess re-identification risk. Failed cohorts are automatically routed back to the generator with corrective feedback, creating a closed-loop system that ensures output quality and regulatory compliance before data is released.

The central workflow engine (e.g., built on LangGraph or Temporal) that coordinates all agents, manages state, and handles exceptions. It integrates with enterprise systems to authenticate user requests, check data use agreements, apply appropriate differential privacy parameters, and trigger the generation pipeline. Upon successful validation, it automatically packages and delivers the synthetic cohort to secure research sandboxes, clinical trial simulation platforms, or data catalogs, creating a fully automated, self-service provisioning workflow.

A mandatory component for regulated environments, this system automatically creates an immutable audit trail for every synthetic cohort. It logs the source data statistics (aggregate only), all generation parameters, the version of each agent model used, every validation score, and all downstream access events. This provides the defensible documentation required for IRB submissions, internal governance, and regulatory inquiries, turning a complex generative process into a transparent, auditable asset.